HBM Holdings Signals Strong First-Half 2026: Revenue to Rise c.20% to Up to US$125 Million; Profit Seen at US$62-67 Million

Bulletin Express08:25

HBM Holdings Limited (HBM) issued a positive profit alert for the six months ended 30 June 2026, projecting revenue between US$120.00 million and US$125.00 million, versus US$101.00 million in the prior-year period. The guidance implies year-on-year growth of roughly 18.80%–23.76%.

Net profit is expected to reach US$62.00 million–US$67.00 million, while total adjusted profit—excluding share-based compensation and other one-off expenses—is forecast at US$70.00 million–US$75.00 million.

Management attributed the anticipated uplift to: 1. Ongoing strategic partnerships with multinational pharmaceutical groups, notably AstraZeneca and Bristol Myers Squibb. 2. Newly signed out-licensing deals, including the collaboration with Solstice Oncology, alongside milestone payments from existing agreements. 3. Accelerating revenue contribution from subsidiary Nona Biosciences through antibody transactions and discovery services such as its project with Lonza.

The figures are derived from unaudited management accounts and remain subject to review by the Board’s audit committee and the company’s external auditors. HBM plans to release its full interim results by end-August 2026.

Investors are advised to exercise caution when dealing in HBM securities until the finalized results are published.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105113388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 08:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105113388","market":"hk","top_or_hot":-1,"title":"HBM Holdings Signals Strong First-Half 2026: Revenue to Rise c.20% to Up to US$125 Million; Profit Seen at US$62-67 Million","media":"Bulletin Express","content":"<p>HBM Holdings Limited (HBM) issued a positive profit alert for the six months ended 30 June 2026, projecting revenue between US$120.00 million and US$125.00 million, versus US$101.00 million in the prior-year period. The guidance implies year-on-year growth of roughly 18.80%–23.76%.</p>\n<p>Net profit is expected to reach US$62.00 million–US$67.00 million, while total adjusted profit—excluding share-based compensation and other one-off expenses—is forecast at US$70.00 million–US$75.00 million.</p>\n<p>Management attributed the anticipated uplift to:  \n1. Ongoing strategic partnerships with multinational pharmaceutical groups, notably AstraZeneca and Bristol Myers Squibb.  \n2. Newly signed out-licensing deals, including the collaboration with Solstice Oncology, alongside milestone payments from existing agreements.  \n3. Accelerating revenue contribution from subsidiary Nona Biosciences through antibody transactions and discovery services such as its project with Lonza.</p>\n<p>The figures are derived from unaudited management accounts and remain subject to review by the Board’s audit committee and the company’s external auditors. HBM plans to release its full interim results by end-August 2026.</p>\n<p>Investors are advised to exercise caution when dealing in HBM securities until the finalized results are published.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Signals Strong First-Half 2026: Revenue to Rise c.20% to Up to US$125 Million; Profit Seen at US$62-67 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Signals Strong First-Half 2026: Revenue to Rise c.20% to Up to US$125 Million; Profit Seen at US$62-67 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-24 08:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM Holdings Limited (HBM) issued a positive profit alert for the six months ended 30 June 2026, projecting revenue between US$120.00 million and US$125.00 million, versus US$101.00 million in the prior-year period. The guidance implies year-on-year growth of roughly 18.80%–23.76%.</p>\n<p>Net profit is expected to reach US$62.00 million–US$67.00 million, while total adjusted profit—excluding share-based compensation and other one-off expenses—is forecast at US$70.00 million–US$75.00 million.</p>\n<p>Management attributed the anticipated uplift to:  \n1. Ongoing strategic partnerships with multinational pharmaceutical groups, notably AstraZeneca and Bristol Myers Squibb.  \n2. Newly signed out-licensing deals, including the collaboration with Solstice Oncology, alongside milestone payments from existing agreements.  \n3. Accelerating revenue contribution from subsidiary Nona Biosciences through antibody transactions and discovery services such as its project with Lonza.</p>\n<p>The figures are derived from unaudited management accounts and remain subject to review by the Board’s audit committee and the company’s external auditors. HBM plans to release its full interim results by end-August 2026.</p>\n<p>Investors are advised to exercise caution when dealing in HBM securities until the finalized results are published.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1105113388","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105113388","pubTimestamp":1784852744,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HBM Holdings Limited (HBM) issued a positive profit alert for the six months ended 30 June 2026, projecting revenue between US$120.00 million and US$125.00 million, versus US$101.00 million in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"HBM Holdings 发出 2026 年上半年强劲信号：收入将增长约 20%，达到 1.25 亿美元；预计利润为6200万至6700万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM Holdings Limited (HBM) issued a positive profit alert for the six months ended 30 June 2026, projecting revenue between US$120.00 million and US$125.00 million, versus US$101.00 million in the prior-year period. The guidance implies year-on-year growth of roughly 18.80%–23.76%.\nNet profit is expected to reach US$62.00 million–US$67.00 million, while total adjusted profit—excluding share-based compensation and other one-off expenses—is forecast at US$70.00 million–US$75.00 million.\nManagement attributed the anticipated uplift to:  \n1. Ongoing strategic partnerships with multinational pharmaceutical groups, notably AstraZeneca and Bristol Myers Squibb.  \n2. Newly signed out-licensing deals, including the collaboration with Solstice Oncology, alongside milestone payments from existing agreements.  \n3. Accelerating revenue contribution from subsidiary Nona Biosciences through antibody transactions and discovery services such as its project with Lonza.\nThe figures are derived from unaudited management accounts and remain subject to review by the Board’s audit committee and the company’s external auditors. HBM plans to release its full interim results by end-August 2026.\nInvestors are advised to exercise caution when dealing in HBM securities until the finalized results are published.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105113388","isCrawlerRequest":true}